Cidara Therapeutics Inc

Cidara Therapeutics — Investor Day (July 2022)

57 slides from Cidara Therapeutics's investor day presentation, Jul 7, 2022

  1. Slide 1: DFCs: a new class of drugs breaking ground in anti-virals and oncology

    Slide 1: DFCs: a new class of drugs breaking ground in anti-virals and oncology

    1 D F C s : a n e w c l a s s o f d r u g s b r e a k i n g g r o u n d i n a n t i - v i r a l s a n d o n c o l o g y J u l y 7 , 2 0 2 2

  2. Slide 2: Forward-looking statements

    Slide 2: Forward-looking statements

    2 T h e s e s l i d e s c o n t a i n f o r w a r d - l o o k i n g s t a t e m e n t s w i t h i n t h e m e a n i n g o f t h e P r i v a t e S e c u r i t i e s L i t i g a t i o n R e f o r m A c t o f 1 9 9 5 . The words “may,” “will,” “estimate,” “plan”, “anticipate,” “expect,” “potential,” “c

  3. Slide 3: Research & Development Day, Thursday, July 7, 2022

    Slide 3: Research & Development Day, Thursday, July 7, 2022

    Research & Development Day Thursday, July 7, 2022

  4. Slide 4: Rezafungin and Cloudbreak platforms

    Slide 4: Rezafungin and Cloudbreak platforms

    4 R e z a f u n g i n a n d C l o u d b r e a k p l a t f o r m s REZAFUNGIN CLOUDBREAK • Echinocandin antifungal treatment & prevention • Positive Phase 3 data • Expected PDUFA Q1 2023 • Novel immunotherapy platform: antiviral & oncology • Clinical stage (influenza) • Opportunity to drive future va

  5. Slide 5: Both platforms provide additional ongoing and future value

    Slide 5: Both platforms provide additional ongoing and future value

    5 B o t h p l a t f o r m s p r o v i d e a d d i t i o n a l o n g o i n g a n d f u t u r e v a l u e ~$568M P h a s e 2 d a t a ( 2 0 1 9 ) ~$780M P r e c l i n i c a l d a t a ( 2 0 2 1 ) REZAFUNGIN CLOUDBREAK

  6. Slide 6: Both platforms provide additional ongoing and future value

    Slide 6: Both platforms provide additional ongoing and future value

    6 B o t h p l a t fo r m s p ro v i d e a d d i t i o n a l o n g o i n g a n d f u t u re va l u e ~$568M P h a s e 2 d a t a ( 2 0 1 9 ) ~$780M P r e c l i n i c a l d a t a ( 2 0 2 1 ) REZAFUNGIN CLOUDBREAK PROGRAM: antifungal RIGHTS: ex-US/Japan • $30M upfront • $9M equity investment • $42M in d

  7. Slide 7: Both platforms provide additional ongoing and future value

    Slide 7: Both platforms provide additional ongoing and future value

    7 B o t h p l a t fo r m s p ro v i d e a d d i t i o n a l o n g o i n g a n d f u t u re va l u e ~$568M P h a s e 2 d a t a ( 2 0 1 9 ) ~$780M P r e c l i n i c a l d a t a ( 2 0 2 1 ) REZAFUNGIN CLOUDBREAK PROGRAM: antifungal RIGHTS: ex-US/Japan PROGRAM: influenza DFC RIGHTS: global • $27M upfro

  8. Slide 8: Rezafungin update

    Slide 8: Rezafungin update

    8 R e z a f u n g i n u p d a t e REZAFUNGIN • Echinocandin antifungal treatment & prevention • Positive Phase 3 data • Expected PDUFA Q1 2023

  9. Slide 9: Rezafungin update

    Slide 9: Rezafungin update

    9 R e z a f u n g i n u p d a t e REZAFUNGIN • Echinocandin antifungal treatment & prevention • Positive Phase 3 data • Expected PDUFA Q1 2023 Rezafungin will be commercialized by third parties in US and Japan • Cidara does not intend to fund commercialization costs • In discussions for US licensing

  10. Slide 10: Cidara's new strategic focus: Cloudbreak program

    Slide 10: Cidara's new strategic focus: Cloudbreak program

    10 C i d a r a ’ s n e w s t r a t e g i c f o c u s : C l o u d b r e a k D F C p r o g r a m REZAFUNGIN CLOUDBREAK Anti-Fungal Treatment and Prevention Drug Fc Conjugates with broad clinical application

  11. Slide 11: Today's panel members

    Slide 11: Today's panel members

    11 To d ay ’s p a n e l m e m b e rs Ezra Cohen, MD Chief of Hematology-Oncology UCSD Perry Nisen, MD, PhD CEO, Quanta Therapeutics

  12. Slide 12: Today's panel members

    Slide 12: Today's panel members

    12 T o d a y ’ s p a n e l m e m b e r s Ezra Cohen, MD Chief of Hematology-Oncology UCSD Perry Nisen, MD, PhD CEO, Quanta Therapeutics Leslie Tari, PhD Chief Scientific Officer, Cidara

  13. Slide 13: Agenda

    Slide 13: Agenda

    13 13 A g e n d a Drug Fc Conjugates what they are (and are not) Les Tari, PhD Advantages of DFCs over conventional modalities in Influenza, SARS and oncology Les Tari, PhD Clinical Potential in oncology Perry Nisen, MD, PhD Ezra Cohen, MD

  14. Slide 14: Cloudbreak creates a new class of drug conjugates: DFCs

    Slide 14: Cloudbreak creates a new class of drug conjugates: DFCs

    14 C LO U D B R E A K ® c re a t e s a n e w c l a s s o f d r u g c o n j u ga t e s : “ D F C s ” Drug Fc Conjugate

  15. Slide 15: Fc moiety is tailored to specific indications

    Slide 15: Fc moiety is tailored to specific indications

    15 F c m o i e t y i s t a i l o r e d t o t o s p e c i f i c i n d i c a t i o n s • IgG1 • Engineered to enhance FcRn binding • Improves half-life compared to wt Fc • Master cell bank established for manufacturing • IgG1 and IgG4 • IgG1 versions mutated to reduce immune effector function • IgG4 l

  16. Slide 16: Different types of targeting moieties attach to the Fc moiety

    Slide 16: Different types of targeting moieties attach to the Fc moiety

    16 D i f fe re n t t y p e s o f ta rg e t i n g m o i e t i e s ( T M s ) a t ta c h t o t h e Fc m o i e t y SMALL MOLECULES PEPTIDE FUSIONS Fc MOIETY Directed against surface target active sites. Example: Neuraminidase in CD388. Designed to inhibit protein-protein interactions. Example: SARS spik

  17. Slide 17: Targeting moieties are directed against validated targets

    Slide 17: Targeting moieties are directed against validated targets

    17 T a r g e t i n g m o i e t i e s a r e d i r e c t e d a g a i n s t v a l i d a t e d t a r g e t s INFLUENZA: neuraminidase CANCER: adenosine-signaling pathway SARS: spike protein ACE-2 receptor interaction

  18. Slide 18: Potential advantages

    Slide 18: Potential advantages

    18 Po t e n t i a l D F C a d va n ta g e s

  19. Slide 19: DFCs are fundamentally different from ADCs

    Slide 19: DFCs are fundamentally different from ADCs

    19 19 D F C s a re f u n d a m e n ta l l y d i f fe re n t f ro m A D C s ADC DFC SM Cytotoxin SM drug conjugate Tumor cell

  20. Slide 20: ADCs employ mAbs directed to cell surface epitopes

    Slide 20: ADCs employ mAbs directed to cell surface epitopes

    20 20 A D C s e m p l o y m A b s d i re c t e d t o c e l l s u r fa c e e p i t o p e s … DFCTumor cell ADC SM drug conjugate

  21. Slide 21: ADCs are internalized by cancer cells to release cytotoxic payloads

    Slide 21: ADCs are internalized by cancer cells to release cytotoxic payloads

    21 … a n d a re i n t e r n a l i ze d b y c a n c e r c e l l s t o re l e a s e c y t o t ox i c p ay l o a d s DFCTumor cell ADC SM drug conjugate

  22. Slide 22: DFCs inhibit catalytic activity of surface exposed targets

    Slide 22: DFCs inhibit catalytic activity of surface exposed targets

    22 22 DFC SM drug conjugate Tumor cell ADC D F C s i n h i b i t c a t a l y t i c a c t i v i t y o f s u r f a c e e x p o s e d t a r g e t s … CD73 CD73 Tumor cell

  23. Slide 23: DFCs are inherently less toxic than ADCs

    Slide 23: DFCs are inherently less toxic than ADCs

    23 23 DFC CD73 CD73 SM drug conjugate Tumor cell ADC … a n d a r e i n h e r e n t l y l e s s t o x i c t h a n A D C s Tumor cell

  24. Slide 24: DFCs can accommodate multiple targeting moieties

    Slide 24: DFCs can accommodate multiple targeting moieties

    24 24 D F C s c a n a c c o m m o d a t e m u l t i p l e ta rg e t i n g m o i e t i e s ADC DFC SM Cytotoxin SM drug conjugate

  25. Slide 25: DFCs can accommodate multiple targeting moieties

    Slide 25: DFCs can accommodate multiple targeting moieties

    25 25 D F C s c a n a c c o m m o d a t e m u l t i p l e t a r g e t i n g m o i e t i e s DFC SM drug conjugate Peptide fusion Peptide fusion SM drug conjugate ADC SM Cytotoxin

  26. Slide 26: DFCs have advantages over small molecule therapeutics

    Slide 26: DFCs have advantages over small molecule therapeutics

    26 D F C s h av e a d va n ta g e s o v e r s m a l l m o l e c u l e t h e ra p e u t i c s Potency Distribution to compartments outside plasma (e.g., lung) Oral bioavailability, cell penetration Lipinski’s rules Potentially limited by cell penetration, properties Extra- and intra-cellular compartm

  27. Slide 27: DFCs have advantages over antibodies

    Slide 27: DFCs have advantages over antibodies

    27 D F C s h a v e a d v a n t a g e s o v e r a n t i b o d i e s Able to target cryptic sites, small molecule binding pockets Able to modulate drug-Fc-ratio to increase potency Able to install 2 or more discrete targeting moieties Distribution to compartments outside plasma (e.g., lung) Monoclonal

  28. Slide 28: Janssen collaboration on CD388

    Slide 28: Janssen collaboration on CD388

    28 J a n s s e n c o l l a b o r a t i o n o n C D 3 8 8 D F C

  29. Slide 29: Janssen recognized the shortcomings of the flu vaccine and antibodies

    Slide 29: Janssen recognized the shortcomings of the flu vaccine and antibodies

    29 J a n s s e n re c o g n i ze d t h e s h o r t c o m i n g s o f t h e f l u va c c i n e a n d a n t i b o d i e s Universal protection: multiple viruses Potential to protect all high risk groups Potential for prevention and treatment Scale and cost Vaccines High Yes AttractiveAttractive No Low

  30. Slide 30: CD388 is in clinical trials for universal influenza prevention

    Slide 30: CD388 is in clinical trials for universal influenza prevention

    30 C D 3 8 8 i s i n c l i n i c a l t r i a l s f o r u n i v e r s a l i n f l u e n z a p r e v e n t i o n Universal protection: all strains Potential to protect all high risk groups Potential for prevention and treatment Scale and cost High Yes Attractive DFCs Yes CD388 is being developed for u

  31. Slide 31: DFCs designed for universal SARS-2 prevention

    Slide 31: DFCs designed for universal SARS-2 prevention

    31 Peptide fusion D F C s d e s i g n e d f o r ” U n i v e r s a l ” S A R S - 2 p r e v e n t i o n Universal protection: multiple viruses Potential to protect all high risk groups Potential for prevention and treatment Scale and cost High Yes Attractive DFCs Yes • Peptide engineered to maximize a

  32. Slide 32: Targeting the ACE-spike protein interaction limits viral escape options

    Slide 32: Targeting the ACE-spike protein interaction limits viral escape options

    32 SARS-2 T a r g e t i n g t h e A C E 2 - s p i k e p r o t e i n i n t e r a c t i o n l i m i t s v i r a l e s c a p e o p t i o n s ACE2 Receptor Fc is being optimized to bind respiratory mucosa for inhaled dosing Peptide is being optimized for stability Peptide has been engineered for compati

  33. Slide 33: Cidara's DFC covers all known SARS-2 variants

    Slide 33: Cidara's DFC covers all known SARS-2 variants

    33 C i d a r a ’ s S A R S - 2 D F C c o v e r s a l l k n o w n v a r i a n t s mapped on the delta variant spike (PDB code 7WBQ) BA.1 Mutations in CTP-A binding site observed in all omicron sub-lineages observed only in BA.1 Delta variant spike protein CTP-A

  34. Slide 34: Potential for universal coverage of all SARS-2 strains

    Slide 34: Potential for universal coverage of all SARS-2 strains

    34 P o t e n t i a l f o r u n i v e r s a l c o v e r a g e o f a l l S A R S - 2 s t r a i n s 0.0 0.50.40.30.20.1 0.130.07 Early Variant D614G/B.1 Delta B.1.617.2 Omicron BA.1/B1.1.529 Omicron/BA.2/B.1/B1.1.529 0.13 0.15 0.21 POTENCYHigher LowermAb1,2 Cidara DFC3 Spike binding IC50 (nM) (ELISA) 1

  35. Slide 35: Potential for universal coverage of all SARS-2 strains

    Slide 35: Potential for universal coverage of all SARS-2 strains

    35 P o t e n t i a l f o r u n i v e r s a l c o v e r a g e o f a l l S A R S - 2 s t r a i n s 0.0 Early Variant D614G/B.1 Delta B.1.617.2 Omicron BA.1/B1.1.529 Omicron/BA.2/B.1/B1.1.529 5.04.03.02.01.0 6.00.5 0.15 Spike binding IC50 (nM) (ELISA) mAb1,2 Cidara DFC3 POTENCYHigher Lower 5.93 1. The

  36. Slide 36: Potential for universal coverage of all SARS-2 strains

    Slide 36: Potential for universal coverage of all SARS-2 strains

    36 P o t e n t i a l f o r u n i v e r s a l c o v e r a g e o f a l l S A R S - 2 s t r a i n s Early Variant D614G/B.1 Delta B.1.617.2 Omicron BA.1/B1.1.529 Omicron/BA.2/B.1/B1.1.529 0.130.07 0.13 0.15 0.21 0.470.14 0.0 0.50.40.30.20.1 mAb1,2 Cidara DFC3 Spike binding IC50 (nM) (ELISA) POTENCYHigh

  37. Slide 37: Spike-binding data is supported by in vivo efficacy

    Slide 37: Spike-binding data is supported by in vivo efficacy

    37 37 S p i k e - b i n d i n g d a t a i s s u p p o r t e d b y i n v i v o e f f i c a c y LOD Lung burden 4 days post-infection Intranasal dosing Omicron BA.1/B1.1.529, in Syrian Hamsters 1mg dose, 6 hrs prior to infection p = 0.0152

  38. Slide 38: SARS-'Flu DFCs could protect against the two major respiratory viruses

    Slide 38: SARS-'Flu DFCs could protect against the two major respiratory viruses

    38 S A R S - ’ F l u D F C s c o u l d p r o t e c t a g a i n s t t h e t w o m a j o r r e s p i r a t o r y v i r u s e s Universal protection: multiple viruses Potential to protect all high risk groups Potential for prevention and treatment Scale and cost High Yes Attractive DFCs Yes Flu and SAR

  39. Slide 39: Immune checkpoint pathways

    Slide 39: Immune checkpoint pathways

    39 I m m u n e c h e c k p o i n t p a t h w ay s

  40. Slide 40: Few patients respond to checkpoint monotherapies

    Slide 40: Few patients respond to checkpoint monotherapies

    40 40 Fe w e r t h a n 1 5 % o f p a t i e n t s re s p o n d t o c h e c k p o i n t m o n o t h e ra p i e s 1 T-Cell Tumor Cell PD-L1PD-1 Interaction silences T-cell Several inhibitors on market. E.g., Keytruda binds PD-1 1. Haslam and Prasad,. JAMA Netw Open. 2019;2(5):e192535. doi:10.1001/jaman

  41. Slide 41: Few patients respond to checkpoint monotherapies

    Slide 41: Few patients respond to checkpoint monotherapies

    41 41 F e w e r t h a n 1 5 % o f p a t i e n t s r e s p o n d t o c h e c k p o i n t m o n o t h e r a p i e s 1 Tumor Cell T-Cell Dampens immune response Several inhibitors in development T-Cell PD-L1PD-1 Interaction silences T-cell Several inhibitors on market. E.g., Keytruda binds PD-1 1. Hasl

  42. Slide 42: Discussion

    Slide 42: Discussion

    42 D i s c u s s i o n

  43. Slide 43: DFCs have the potential to augment PD-1/PD-L1 therapies

    Slide 43: DFCs have the potential to augment PD-1/PD-L1 therapies

    43 43 D F C s h a v e t h e p o t e n t i a l t o a u g m e n t P D - 1 / P D - L 1 t h e r a p i e s T-Cell Tumor Cell T-Cell PD-L1PD-1 Interaction silences T-cell Several inhibitors on market. E.g., Keytruda binds PD-1 Dampens immune response Several inhibitors in development

  44. Slide 44: DFCs have the potential to augment PD-1/PD-L1 therapies

    Slide 44: DFCs have the potential to augment PD-1/PD-L1 therapies

    44 44 D F C s h a v e t h e p o t e n t i a l t o a u g m e n t P D - 1 / P D - L 1 t h e r a p i e s T-Cell Tumor Cell T-Cell PD-L1PD-1 Interaction silences T-cell Several inhibitors on market. E.g., Keytruda binds PD-1 CD73 CD73 DFC

  45. Slide 45: DFCs have the potential to augment PD-1/PD-L1 therapies

    Slide 45: DFCs have the potential to augment PD-1/PD-L1 therapies

    45 45 D F C s h av e t h e p o t e n t i a l t o a u g m e n t P D - 1 / P D - L 1 t h e ra p i e s PD-L1PD-1 Interaction silences T-cell Several inhibitors on market. E.g., Keytruda binds PD-1 T-Cell Tumor Cell T-Cell A2AR A2AR DFC

  46. Slide 46: CD73 DFCs demonstrate robust anti-tumor activity in mouse models

    Slide 46: CD73 DFCs demonstrate robust anti-tumor activity in mouse models

    46 46 C D 7 3 D F C s d e m o n s t r a t e r o b u s t a n t i - t u m o r a c t i v i t y i n m o u s e m o d e l s Positive control2Vehicle 2. Small molecule AB680 in clinical trials Tumor Volume, Day 121 1. Mouse syngeneic model with a colon tumor cell line (CT26). Scatter plot of individual ani

  47. Slide 47: CD73 DFCs demonstrate robust anti-tumor activity in mouse models

    Slide 47: CD73 DFCs demonstrate robust anti-tumor activity in mouse models

    47 47 C D 7 3 D F C s d e m o n s t r a t e r o b u s t a n t i - t u m o r a c t i v i t y i n m o u s e m o d e l s Positive control2Vehicle Cidara DFC3 2. Small molecule AB680 in clinical trials 3. Molecule CBO-A Tumor Volume, Day 121 1. Mouse syngeneic model with a colon tumor cell line (CT26).

  48. Slide 48: CD73 DFCs demonstrate robust anti-tumor activity in mouse models

    Slide 48: CD73 DFCs demonstrate robust anti-tumor activity in mouse models

    48 C D 7 3 D F C s d e m o n s t r a t e r o b u s t a n t i - t u m o r a c t i v i t y i n m o u s e m o d e l s Positive control2Vehicle Cidara DFC3 2. Small molecule AB680 in clinical trials 3. Molecule CBO-A 1. Mouse syngeneic model with a colon tumor cell line (CT26). Scatter plot of individua

  49. Slide 49: CD73 DFCs demonstrate robust anti-tumor activity in mouse models

    Slide 49: CD73 DFCs demonstrate robust anti-tumor activity in mouse models

    49 49 C D 7 3 D F C s d e m o n s t r a t e r o b u s t a n t i - t u m o r a c t i v i t y i n m o u s e m o d e l s Positive control2Vehicle Cidara DFC3 2. Small molecule AB680 in clinical trials 3. Molecule CBO-A 1. Mouse syngeneic model with a colon tumor cell line (CT26). Scatter plot of indivi

  50. Slide 50: CD73 inhibitors augment PD-1 inhibitor activity

    Slide 50: CD73 inhibitors augment PD-1 inhibitor activity

    50 50 C D 7 3 i n h i b i t o r s a u g m e n t P D - 1 i n h i b i t o r a c t i v i t y 0 21 Tumor cells injected 9 10 15 205 Day 9: ~75 mm3 tumors Day 21: >2000 mm3 tumors

  51. Slide 51: CD73 inhibitors augment PD-1 inhibitor activity

    Slide 51: CD73 inhibitors augment PD-1 inhibitor activity

    51 51 C D 7 3 i n h i b i t o r s a u g m e n t P D - 1 i n h i b i t o r a c t i v i t y 21Tumor Volume, Day 21 Vehicle 15 20 Day 21: >2000 mm3 tumors

  52. Slide 52: CD73 inhibitors augment PD-1 inhibitor activity

    Slide 52: CD73 inhibitors augment PD-1 inhibitor activity

    52 52 C D 7 3 i n h i b i t o rs a u g m e n t P D - 1 i n h i b i t o r a c t i v i t y 21Tumor Volume, Day 21 Vehicle 15 20 Day 21: >2000 mm3 tumors PD-1 mAb

  53. Slide 53: CD73 inhibitors augment PD-1 inhibitor activity

    Slide 53: CD73 inhibitors augment PD-1 inhibitor activity

    53 53 C D 7 3 i n h i b i t o r s a u g m e n t P D - 1 i n h i b i t o r a c t i v i t y 21Tumor Volume, Day 21 Vehicle 15 20 Day 21: >2000 mm3 tumors PD-1 mAb CD73 DFC alone

  54. Slide 54: CD73 inhibitors augment PD-1 inhibitor activity

    Slide 54: CD73 inhibitors augment PD-1 inhibitor activity

    54 54 C D 7 3 i n h i b i t o r s a u g m e n t P D - 1 i n h i b i t o r a c t i v i t y 21Tumor Volume, Day 21 Vehicle 15 20 PD-1 mAb CD73 DFC alone CD73 DFC+ PD-1 mAb

  55. Slide 55: Oncology programs are advancing rapidly

    Slide 55: Oncology programs are advancing rapidly

    55 O n c o l o g y D F C p r o g r a m s a r e a d v a n c i n g r a p i d l y 2022 2023Q2 Q3 Q4 Q2 Q3 Q4 CD73 CD73 / A2AR PD-1/PD-L1 Combination DFCs will be evaluated and added to the pipeline in 2022 as guided by data SOLID TUMOR PROGRAMS Dis Pre IND Ph1 Dis Pre IND Ph1 Dis Pre IND Ph1 Dis Pre IN

  56. Slide 56: How can Cidara succeed in the crowded space of immuno-oncology?

    Slide 56: How can Cidara succeed in the crowded space of immuno-oncology?

    56 56 H o w c a n C i d a r a s u c c e e d i n t h e c r o w d e d s p a c e o f i m m u n o - o n c o l o g y ? FOCUS: ADENOSINE PATHWAY • Relatively limited competition • Improve outcomes either alone or combined with existing agents • Opportunity to create highly potent and safe “single molecule

  57. Slide 57: Discussion

    Slide 57: Discussion

    57 D i s c u s s i o n

Source: SEC EDGAR · 8-K filed Jul 7, 2022

More decks from Cidara Therapeutics Inc